

Dermira, Inc.  
Form 8-K  
March 18, 2019

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): March 18, 2019**

**Dermira, Inc.**

**(Exact Name of the Registrant as Specified in Its Charter)**

**Delaware**

**(State or Other Jurisdiction of Incorporation)**

**001-36668**  
**(Commission)**

**27-3267680**  
**(IRS Employer)**

**File Number)**

**Identification No.)**

**275 Middlefield Road, Suite 150**

**Menlo Park, California**  
**(Address of Principal Executive Offices)**

**94025**  
**(Zip Code)**

**(650) 421-7200**

**(Registrant's Telephone Number, Including Area Code)**

**Not Applicable**

**(Former Name or Former Address, If Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01 Other Events.****Executive Compensation**

The following table provides information regarding all plan and non-plan compensation awarded to, earned by or paid to the principal executive officer, principal financial officer and the three other most highly compensated executive officers of Dermira, Inc. ( *Dermira* ) serving as such at December 31, 2018 (the *Named Executive Officers* ) for all services rendered in all capacities during the year ended December 31, 2018:

Name and Principal Position	Salary	Equity Awards <sup>(1)</sup>	Non-Equity Incentive Plan Compensation <sup>(2)</sup>	All Other Compensation	Total
Thomas G. Wiggans <i>Chief Executive Officer and Chairman of the Board</i>	\$ 572,500	\$ 3,472,353	\$ 326,325		\$ 4,317,178
Andrew L. Guggenlime <i>Chief Financial Officer</i>	406,930	1,798,465	154,633		2,360,028
Lori Lyons-Williams <i>Chief Commercial Officer</i>	392,040	2,050,611	148,975	113,000 <sup>(3)</sup>	2,704,626
Luis Peña <i>Chief Development Officer</i>	409,170	1,954,849	155,485		2,519,504
Christopher Horan <sup>(4)</sup> <i>Chief Technical Operations Officer</i>	300,000	1,744,420	114,000	200,000 <sup>(5)</sup>	2,358,420

- (1) The amounts reported in the *Equity Awards* column represent the grant date fair value of the stock options and restricted stock units granted to the Named Executive Officers during the year ended December 31, 2018 as computed in accordance with Accounting Standards Codification Topic 718. The assumptions used in calculating the grant date fair value of the equity awards reported in this column are set forth in Notes 2 and 9 to the audited consolidated financial statements included in Dermira's annual report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission on February 26, 2019. Note that the amounts reported in this column reflect the accounting cost for these equity awards, and do not correspond to the actual economic value that may be received by our Named Executive Officers therefrom.
- (2) The amounts reported in the *Non-Equity Incentive Plan Compensation* column represent bonuses earned by the Named Executive Officers under Dermira's incentive compensation guidelines recommended by Dermira's compensation committee ( *Compensation Committee* ) of the board of directors (the *Board* ) and approved by the Board for the year ended December 31, 2018. Under the guidelines, Mr. Wiggans was entitled to a target bonus of up to 60% of his base salary, Ms. Lyons-Williams and Messrs. Peña, Guggenlime and Horan were each entitled to a target bonus of up to 40% of his or her base salary. In February 2019, the Compensation Committee determined the actual amounts of the incentive bonuses for the year ended December 31, 2018 based on Dermira's achievement of corporate objectives. Bonuses of approximately 95% of the target bonuses were paid to the Named Executive Officers based on Dermira's achievement of corporate objectives.
- (3) Represents payments made pursuant to a housing assistance arrangement, which provides for gross cash payments to Ms. Lyons-Williams on the last day of each month beginning June 30, 2017 for a three-year period equal to \$10,000 monthly for the first 12-month period, \$9,000 monthly for the second 12-month period, and

Edgar Filing: Dermira, Inc. - Form 8-K

\$8,000 monthly for the third 12-month period, in each case, subject to applicable tax withholdings.

- (4) Mr. Horan joined Dermira as its Chief Technical Operations Officer in April 2018.
- (5) Represents a one-time cash bonus payment made in connection with Mr. Horan's commencement of employment with Dermira.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**DERMIRA, INC.**

Date: March 18, 2019

By: /s/ Andrew L. Guggenime  
Andrew L. Guggenime  
Chief Financial Officer